HYPERA S A/S (OTCMKTS:HYPMY) Rating Increased to Buy at HSBC

HSBC upgraded shares of HYPERA S A/S (OTCMKTS:HYPMY) from a hold rating to a buy rating in a report released on Wednesday morning, The Fly reports.

Separately, ValuEngine upgraded HYPERA S A/S from a sell rating to a hold rating in a research note on Tuesday, March 31st.

Shares of OTCMKTS:HYPMY opened at $6.86 on Wednesday. HYPERA S A/S has a 52-week low of $4.51 and a 52-week high of $9.53. The stock has a market cap of $4.34 billion, a price-to-earnings ratio of 16.21 and a beta of 1.13. The company has a quick ratio of 2.55, a current ratio of 2.99 and a debt-to-equity ratio of 0.16. The business has a 50-day moving average price of $6.32 and a 200-day moving average price of $6.67.

About HYPERA S A/S

Hypera SA operates as a pharmaceutical company in Brazil. The company offers prescription medications under the Farmasa, Neo Química, and Luper brands; and over-the-counter medications comprising laxative, antacid, antispasmodic, topical antiseptic, topical, nasal decongestant, and other drugs under Gelol, Anapyon, Biotônico Fontoura, Epocler, Merthiolate, Tamarine, and Rinosoro brands.

See Also: Hedge Funds

The Fly

Receive News & Ratings for HYPERA S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HYPERA S A/S and related companies with MarketBeat.com's FREE daily email newsletter.